Pre-made Urelumab benchmark antibody ( Whole mAb, anti-TNFRSF9/CD137 therapeutic antibody, Anti-ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-604
Pre-Made Urelumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Urelumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6mhr:AB:DE|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Companies||Bristol-Myers Squibb;National Cancer Institute (USA);Ono Pharmaceutical;Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;University of Chicago;Medarex|
|Conditions Active||Non-Hodgkin's lymphoma;Solid tumours;Glioblastoma;Multiple myeloma|
|Conditions Discontinued||Colorectal cancer;Head and neck cancer;Malignant melanoma;Non-small cell lung cancer|
|Development Tech||Medarex UltiMAb Mouse|